FDA approves new formulation of Lumigan with less drug exposure

- Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions - http://eyedocnews.com -

New Lumigan Eye Drop Formulation for Glaucoma From Allergan Approved by FDA

Posted By Dr. Ari Weitzner On September 1, 2010 @ 12:58 pm In Glaucoma | Comments Disabled

Allergan has announced that the FDA has approved has approved LUMIGAN^(R) (bimatoprost ophthalmic solution) 0.01% as a first-line therapy for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. LUMIGAN^(R) 0.01% is an optimized reformulation of LUMIGAN^(R) (bimatoprost ophthalmic solution) 0.03%.

The approval followed a study showing that in patients with open-angle glaucoma or ocular hypertension with an average baseline of 23.5 mm Hg, LUMIGAN^(R)0.01% lowered IOP up to 7 mm Hg from baseline, with only one-third the drug exposure of LUMIGAN^(R) 0.03%.

Read the full release ^[1] issued by Allergan.

Article printed from Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions: http://eyedocnews.com

URL to article: http://eyedocnews.com/003525-new-lumigan-eye-drop-formulation-for-glaucoma-from-allergan-approved-by-fda/

URLs in this post:

[1] Read the full release: http://agn.client.shareholder.com/releasedetail.cfm?ReleaseID=503812

Click here to print.